The RxSight ® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens ® (LAL™/LAL+ ®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first ...

Piper Sandler initiated coverage of RxSight (RXST) with a Neutral rating and $18 price target The firm likes the company’s novel light ...

RxSight projects the sale of 27,579 Light Adjustable Lenses (LAL/LAL+), with a growth of 36%Y/Y increase in procedure volume. Also, the company anticipates the sale of 73 Light Delivery Devices ...

These factors led to a year-over-year decline in same-store sales of Light Adjustable Lenses (LALs ... clinical data to highlight the benefits of RxSight’s adjustable IOL platform.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $36.5, a high estimate of $66.00, and a low estimate of $17.00. Experiencing a 18.74% decline, ...

April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device ... driven by: The sale of 27,579 Light Adjustable Lenses (LAL™/LAL+ ®); representing a 36% increase in ...

April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic ... The sale of 27,579 Light Adjustable Lenses (LAL™/LAL+ ®); representing a 36% increase in procedure volume ...

Sold 27,579 Light Adjustable Lenses (LALs), up 36% year-over-year. LDD installed base increased to 1,044 units, up 43% year-over-year. RxSight revised its 2025 revenue guidance to $160-175 million ...